Silencing of the p53R2 gene by RNA interference inhibits growth and enhances 5-fluorouracil sensitivity of oral cancer cells
スポンサーリンク
概要
- 論文の詳細を見る
The p53R2 gene encodes the ribonucleotide reductase (RR) small subunit 2 homologue, and is induced by several stress signals activating p53, such as DNA-damaging agents. The p53R2 gene product causes an increase in the deoxynucleotide triphosphate (dNTP) pool in the nucleus, which facilitates DNA repair and synthesis. We hypothesized that p53R2 would be a good molecular target for cancer gene therapy. In this study, three human oral cancer cell lines (SAS, HSC-4 and Ca9-22), a human breast cancer cell line MCF-7, and a normal human fibroblast cell line NHDF were tested. We silenced the expression of p53R2 with the highly specific post-transcriptional suppression of RNA interference (RNAi). We investigated p53R2 expression with the reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting. The sensitivity to anticancer agents was evaluated by a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. The expression of p53R2 showed no association with the mutational status of p53. The cancer cell lines with higher p53R2 expression were more resistant to 5-FU. RNAi-mediated p53R2 reduction selectivity inhibited growth and enhanced chemosensitivity in cancer cell lines but not in normal fibroblasts. These results suggest that basal transcription of p53R2 could be associated with the sensitivity to anticancer agents. Moreover, we assessed the possibility that p53R2 would be a good molecular target, and report that RNAi targeting of p53R2 could be useful for oral cancer gene therapy.
- 2005-06-01
論文 | ランダム
- 前立腺癌診断において Free/TotalPSA比は有用か(第93回日本泌尿器科学会総会)
- 武蔵野赤十字病院における前立腺がんの最近の動向 : 病診連携の観点から(第93回日本泌尿器科学会総会)
- 複数回の生検にて検出に至った前立腺癌症例の検討(第93回日本泌尿器科学会総会)
- 2-107 遠心分離法および濾過法を用いた析出結晶物質の回収((05)実験・実技-II,口頭発表論文)
- 3P029 超遠心分析沈降速度法を用いたTRAP-antiTRAP相互作用解析(蛋白質-構造機能相関,第48回日本生物物理学会年会)